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In this paper, we describe our experience in the treatment of childhood 
empyema using urokinase. Patients’ ages ranged from 2 to 12 years. Urokinase 
(dosage: 3,100 IU/kg/day) was diluted in normal saline to produce 1000 IU/ml 
(maximum dosage 100,000 IU in 100 ml of normal saline). After 2 hours, 
the clamped catheters were released and connected to water-seal suction at a 
negative pressure of 10 cm H2O. Pleural irrigations were continued once a day 
until thoracostomy tube output decreased to less than 10 ml/day (urokinase 
treatment mean duration: 11.5 days). The complete resolution of the chest 
effusion was assessed on chest ultrasound scan and radiographs. None of 
the patients experienced any side effects due to urokinase. It would now 
seem reasonable to advocate small chest tube thoracostomy and intrapleural 
urokinase as first-line treatment of pleural empyema in children, with surgery 
indicated as a secondary intervention. 
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Pleural effusion is a common complication of 
pediatric bacterial pneumonia, occurring with 
an incidence of 3.3 per 100,000 children1. When 
such effusions become loculated or progress to 
empyema formation, tube thoracostomy may 
become a necessary adjunct to thoracentesis 
and antibiotic therapy. Although video-assisted 
thoracoscopy or thoracotomy and decortication 
are effective surgical options in the management 
of complicated pleural effusion, in recent years, 
some pediatric reports have described the 
successful use of intrapleural instillation of 
fibrinolytic agents as treatment for persistent 
empyemas7,12. 
Tillet and Sherry¹¹ reported the use of a 
mixture of streptokinase and streptodornase 
for intrapleural fibrinolysis in 1949. Urokinase 
was introduced in 1987 and became the 
most frequently used agent for fibrinolysis 
because of concerns about the antigenicity of 
streptokinase.
This report describes our results with 
intrapleural instillation of urokinase in the 
management of multiloculated pleural effusion 
in children.
Material and Methods 
A series of five children (3 girls, 2 boys) is 
reported. In all patients, anteroposterior and 
decubitus standard chest radiographs showed 
pleural effusion. The patients’ ages ranged from 
2 to 12 years (mean: 7) (Table I).
Indications for chest tube drainage included: 1) 
evidence of massive pleural effusion detected on 
chest ultrasonography or computed tomography 
(CT) chest scan (Figs. 1, 2), and 2) clinical 
deterioration in the patient’s condition, as 
evidenced either by severe respiratory distress 
or systemic infection not responding to systemic 
treatment (Table II).
Drainage was performed under sterile 
conditions, light general anesthesia and local 
anesthesia. The chest tube was positioned 
through the “safe triangle”4, bordered by 
the anterior border of the latissimus dorsi, 
the lateral border of the pectoralis major 
muscle, a line superior to the horizontal level 
of the nipple, and an apex below the axilla. 
Two chest tubes (Portex ® Standard Trocar 
The Turkish Journal of Pediatrics 2010; 52: 274-277 Original
Catheter Soft) were inserted in each patient. 
We believe that two chest tu bes enlarge both 
the drainage and the instillation areas. After 
drain placement, fluid was aspirated until no 
more could be obtained. Specimens of the 
pleural fluid were sent to the laboratory for 
chemical and bacteriologic analysis.
Indication for intrapleural urokinase instillation 
was the   presence of large loculations of fluid 
on chest ultrasound scan. For each patient, 
coagulation studies were recorded, including 
prothrombin time, partial thromboplastin time, 
international normalized ratio, and fibrinogen 
split products. The criterion for initiating 
fibrinolysis was decreasing thoracostomy tube 
output during an 8-24-hour period. Urokinase 
(Urochinasi Crinos, Sirton Pharmaceuticals, 
Italy) dose was 3,100 IU/kg/day; it was diluted 
in normal saline to produce 1000 IU/ml12. 
Intrapleural irrigation was performed once 
daily; the tubes were clamped for 2 hours and 
then left open with underwater suction of -10 
cm H2O. This treatment was repeated daily 
until the tube thoracostomy output decreased 
to less than 10 ml/day.
The effectiveness of treatment was assessed 
clinically, biochemically (white cell count and 
C-reactive protein [CRP]), and radiologically, 
with standard chest X-ray and ultrasound every 
3 and 2 days, respectively. 
Results 
Five consecutive patients, who had persistence 
of pleural fluid with associated symptoms and 
inadequate drainage with tube thoracostomy 
alone, received urokinase as adjunctive 
treatment. The etiology of pleural effusion was 
acute pulmonary infection. The pleural fluid 
chemical analysis determined that all effusions 
were exudates. In four cases, bacteriological 
evaluations including Gram’s stain and cultures 
were negative. Case 2 was found positive 
to Staphylococcus aureus. All patients received 
antibiotics before thoracentesis was performed, 
mainly because they were admitted primarily 
in the pediatric department. Streptococcus 
pneumoniae urinary antigen test result was 
positive in Cases 1 and 4; Cases 2, 3 and 5 
were negative. 
Patient
No.
Age
(yr)
Sex
Etiology of pleural 
effusion
Pleural fluid analysis
Glucose  Protein
(mg\dl)       (g\L)
Time from 
admission to 
UK treatment 
(d) 
No. of instil-
lations
Results
1 9 F Parapneumonic 24
21
<20
<20
51
50
50
54
9 12 Resolution
2 12 F Parapneumonic 6 11 Resolution
3 3 M Parapneumonic 8 11 Resolution
4 10 F parapneumonic 9 12 Resolution 
5 2 M Parapneumonic <10 40 7 10 Resolution
Table I. Summary of Patient Data, Pleural Fluid Analysis, Management and Results
Fig. 1. CT chest scan showing massive left 
pleural effusion.
Fig. 2. Transverse ultrasound image of the lower 
portion of the chest shows multiple thin linear   
septations within the pleural fluid.
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Urokinase instillation started when chest tube 
drainage had ceased or almost ceased for at 
least 24 hours (mean initiating time: 8 days 
from chest tube placement). Pleural irrigations 
were continued once a day until thoracostomy 
tube output decreased to less than 10 ml/day 
(urokinase treatment mean duration: 11.5 
days). In all patients, improvement was gradual. 
The complete resolution of the chest effusion 
was assessed on chest ultrasound scan and 
radiographs. Data results are summarized in 
Table I. 
None of the patients experienced any side 
effects due to urokinase.
Discussion 
Pleural effusions are a common complication 
of pediatric bacterial pneumonias, occurring 
with a reported frequency ranging from 21 to 
91%5. If inadequately treated, empyema may 
progress through three stages: stage I, the 
exudative stage; stage II, the fibrinopurulent 
stage; and stage III, the organizing stage. 
The latter occurs when fibroblasts grow into 
the exudate and change the membrane to an 
inelastic “peel” that completely prevents lung 
expansion. This stage may require surgical 
intervention. The traditional approach to 
managing childhood empyema has been to 
advocate an aggressive surgical approach 
with early thoracotomy or preferably “mini” 
thoracotomy and decortication. Recently, 
several reports have described the revival of 
intrapleural fibrinolytic therapy using agents 
such as streptokinase and urokinase, even in 
pediatric patients6,10,12. Intrapleural fibrinolytic 
therapy was first introduced in 1949 by Tillet 
and Sherry¹¹, who instilled streptokinase to the 
pleural space to lyse fibrinous pleural material. 
Urokinase was first introduced in 1989 by 
Moulton et al.8, who treated loculated pleural 
effusion in adults. The first intrapleural use of 
urokinase in children was reported in 1993 by 
Handman et al.2
Until 2006, our traditional management 
of pleural empyemas was thoracoscopic 
“debridement” or thoracotomy and decortication 
(case not reported in this series). We initiated 
this treatment regimen after successfully 
managing a little girl who had failed traditional 
surgical management after undergoing a 
thoracotomy and decortication (case not 
reported in this series). Since then, we decided 
to introduce the intrapleural fibrinolysis 
instillation as the first-line intervention in 
children with complicated parapneumonic 
effusion. 
The mean length of treatment in our study was 
11.5 days. This is longer than that reported 
in some other pediatric series1,7,12. The reason 
could be explained by the fact that we chose 
arbitrarily to discontinue the treatment when 
chest tube output was less than 10 ml/day. 
Nevertheless, none of our patients experienced 
any side effects due to urokinase.
The optimal dosage of urokinase remains to be 
defined. We administered 3,100 IU/kg diluted 
in normal saline to produce a concentration 
of 1,000 IU/ml12, once a day. The maximum 
dosage did not exceed 100,000 IU in 100 ml 
of normal saline.
As has been observed elsewhere,  the 
identification of causative pathogens in our 
study was very low, probably because of 
the broad spectrum antibiotic treatment 
administered before pleural aspiration9.
At the time of hospital discharge, residual 
pleural thickening was observed in our patients, 
but complete normalization was observed 
during the follow-up.
In conclusion, it would now seem reasonable 
to advocate small chest tube thoracostomy and 
intrapleural urokinase as first-line treatment 
of empyema thoracis in children, with surgery 
indicated as a secondary intervention.
Infants Temperature > 38.5°C
Respiratory rate >70 breaths/min
SpaO2 < 94%
Older children Temperature > 38.5°C
Respiratory rate > 50 breaths/min
Severe difficult breathing
SpaO2 < 94%
Table II. Clinical Severity Assessment
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